BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250827T140000
DTEND;TZID=America/New_York:20250827T150000
DTSTAMP:20260515T025702
CREATED:20250811T132405Z
LAST-MODIFIED:20250811T134758Z
UID:71300-1756303200-1756306800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Pfizer On Subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience
DESCRIPTION:Date: Wednesday\, August 27th\, 2025\nTime: 2:00pm – 3:00pm ET \n  \n \n  \n  \n  \n  \n \nWEBINAR TITLE: \nJuggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience. \nOBJECTIVES: \nTo educate attendees on challenges\, shared decision making in hemophilia and introduce HYMPAVZI pen\, dosage\, administration\, and real-world patient experience with HYMPAVZI. \nAUDIENCE: \nAll HTC Staff\, Physicians\, Nurses\, Pharmacists\, etc. \nSPEAKER: \nSteven Pipe\, MD. \nDr. Steven Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan\, Ann Arbor\, Michigan\, USA. He is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy. He was the 2015 recipient of the Leadership in Research Award from the National Hemophilia Foundation. He has served on the Board of Directors for the Hemostasis and Thrombosis Research Society\, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network and most recently as Chair of the Medical and Scientific Advisory Council to the National Hemophilia Foundation.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-pfizer-on-subcutaneous-hympavzi-marstacimab-hncq-learn-more-from-a-real-world-patient-experience/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR